Clinical trial / 2013
Pomegranate extract did not significantly reduce benign prostate tissue oxidative stress.
Seventy men awaiting radical prostatectomy were randomized to take two pomegranate extract tablets or placebo daily for up to four weeks. Pomegranate extract was linked to an 8-hydroxy-2'-deoxyguanosine reduction of 16% in benign tissue, which did not reach statistical significance (P = 0.095). Urolithin A accumulated in prostate tissue in 21 of 33 treated patients versus 12 of 35 controls (P = 0.031), while markers such as Ki67, NF-kappaB, and PSA were unaltered.
- Study type
- Randomized controlled trial
- Who was studied
- 70 men with prostate cancer
- What was measured
- Tissue 8-OHdG levels and prostate cancer biomarkers
THE PAPER
A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy.
Freedland SJ, Carducci M, Kroeger N, Partin A, Rao JY, Jin Y, Kerkoutian S, Wu H, Li Y, Creel P, Mundy K, Gurganus R, Fedor H, King SA, Zhang Y, Heber D, Pantuck AJ. Cancer Prev Res (Phila), 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.